• Launch of Adenuric (febuxostat) in Bahrain, a breakthrough in the management of gout.
• ​Launch of Smectalia (diosmectite) strawberry flavor in Lebanon. Smectalia is the first line treatment of acute and chronic diarrhea for children and adults.

Launch of Zorvolex (diclofenac) in UAE, the first and only FDA-approved low dose nonsteroidal anti-inflammatory drug developed using proprietary SoluMatrix Fine Particle Technology™.

• Launch of Adenuric (febuxostat) in Kingdom of Saudi Arabia, a breakthrough in the management of gout.
• Groundbreaking Ceremony of New Manufacturing plant in Lebanon.

• Launch of Zorvolex (diclofenac) the first and only FDA-approved low dose nonsteroidal anti-inflammatory drug developed using proprietary SoluMatrix Fine Particle Technology™.
• Launch of Livazo (pitavastatin) in Kingdom of Saudi Arabia, a novel efficacious and differentiated statin.
• Launch of Adenuric (febuxostat) in Kuwait, Jordan and United Arab Emirates, a breakthrough in the management of gout.
• Launch of Silosin (silodosin) in Qatar indicated for benign prostatic hyperplasia.

• Launch of Livazo (pitavastatin) in Kuwait and United Arab Emirates, a novel efficacious and differentiated statin.

• Launch of Livazo (pitavastatin) in Jordan under-license from Kowa, a novel efficacious and differentiated statin.
• Algorithm acquired from Ipsen the secondary packaging and marketing authorization for Smecta / Smectalia (diosmectite). Smectalia is the first line treatment of acute and chronic diarrhea for children and adults.

• Launch of Adenuric (febuxostat) in Lebanon under-license from Teijin. Adenuric is a breakthrough in the management of gout.

• Launch of Livazo (pitavastatin) under-license from Kowa in Lebanon, a novel efficacious and differentiated statin

• Launch of Silosin (silodosin, under license from Recordati & Kissei) indicated for benign prostatic hyperplasia. The launch in Lebanon was the 3rd one worldwide after the launches in Japan and United States of America.
• Launch of Zanipress, the only antihypertensive with a fixed combination of a Dihydropiridine Calcium Antagonist (lercanidipine) and an ACE Inhibitor (enalapril), also under license form Recordati

• Regional agreement with Ipsen to promote its portfolio 

• Partnership with Iroko Cardio LLC on Aggrastat (tirofiban). Marketing in the Middle East granted to Algorithm.
• Expansion of the partnership with Lilly to include promotion of products in the Gulf: Glustin, Prozac and Evista

• Partnership with Eli Lilly focusing on the Lebanese market

• Launch of Lercadip (lercanidipine); the first 3rd generation lipophilic Calcium Antagonist Dihydropiridine indicated for Hypertension.
• Launch of the first one shot gynecological antifungal treatment, Lomexin (fenticonazole).
• Launch of Urispas (flavoxate) creating the untapped market of urge incontinence
• Launch of the first generic: Captace (captopril) enhancing the presence of Algorithm in the cardiovascular field

• Partnership with Recordati to manufacture and promote its products in the Middle East, namely Lercadip, Lomexin and Urispas

• Ownership transferred to a group of Lebanese nationals, shareholders of Drogureie de L'Union - distributors of MSD in Lebanon. The company name was changed to ALGORITHM SAL. All manufactured products were still under license from MSD

• Plant established in Lebanon as "CHARLES. E. FROSST & CO. (M.E.) S.A.L". It was initially built in 1961 and later expanded in 1974. It has operated as a subsidiary of MERCK & CO. INC. (MSD) until December 1989.